AR120721A2 - Péptidos y composiciones para el tratamiento de daño articular - Google Patents
Péptidos y composiciones para el tratamiento de daño articularInfo
- Publication number
- AR120721A2 AR120721A2 ARP200103442A ARP200103442A AR120721A2 AR 120721 A2 AR120721 A2 AR 120721A2 AR P200103442 A ARP200103442 A AR P200103442A AR P200103442 A ARP200103442 A AR P200103442A AR 120721 A2 AR120721 A2 AR 120721A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptides
- compositions
- treatment
- joint damage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/17—Angiopoietin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Reivindicación 1: Una composición farmacéutica caracterizada porque comprende un polipéptido que comprende una secuencia de aminoácidos seleccionada de cualquiera de (i) SEQ ID Nº 30, SEQ ID Nº 31, SEQ ID Nº 32, SEQ ID Nº 33, SEQ ID Nº 34, SEQ ID Nº 35, SEQ ID Nº 36, SEQ ID Nº 37, SEQ ID Nº 38, SEQ ID Nº 39, SEQ ID Nº 40, SEQ ID Nº 41, SEQ ID Nº 65, SEQ ID Nº 66, SEQ ID Nº 67, SEQ ID Nº 68, SEQ ID Nº 69, o SEQ ID Nº 70; o (ii) SEQ ID Nº 14, SEQ ID Nº 15, SEQ ID Nº 16, SEQ ID Nº 17, SEQ ID Nº 18, SEQ ID Nº 19, SEQ ID Nº 20, SEQ ID Nº 21, SEQ ID Nº 22, SEQ ID Nº 23, SEQ ID Nº 24, SEQ ID Nº 25, SEQ ID Nº 26, SEQ ID Nº 27, SEQ ID Nº 28, SEQ ID Nº 29, SEQ ID Nº 58, SEQ ID Nº 59, SEQ ID Nº 60, SEQ ID Nº 61, SEQ ID Nº 62, SEQ ID Nº 63, o SEQ ID Nº 64.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361775400P | 2013-03-08 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR120721A2 true AR120721A2 (es) | 2022-03-09 |
Family
ID=51488527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100777A AR095076A1 (es) | 2013-03-08 | 2014-03-10 | Péptidos y composiciones para el tratamiento de daño articular |
ARP200103442A AR120721A2 (es) | 2013-03-08 | 2020-12-11 | Péptidos y composiciones para el tratamiento de daño articular |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100777A AR095076A1 (es) | 2013-03-08 | 2014-03-10 | Péptidos y composiciones para el tratamiento de daño articular |
Country Status (3)
Country | Link |
---|---|
US (8) | US9301971B2 (es) |
AR (2) | AR095076A1 (es) |
MA (1) | MA38369B1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2012DN00572A (es) | 2009-07-14 | 2015-06-12 | Scripps Research Inst | |
JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
MA38369B1 (fr) | 2013-03-08 | 2018-10-31 | Novartis Ag | Peptides et compositions pour le traitement d'une lesion de l'articulation |
CN109963579A (zh) * | 2016-11-14 | 2019-07-02 | 诺华股份有限公司 | 用于治疗软骨损伤和关节炎的方法和组合物 |
TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣3多肽之持續遞送 |
KR102577697B1 (ko) * | 2019-11-13 | 2023-09-14 | 주식회사 나이벡 | 염증 및 상처 치료용 펩타이드 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
JP2002533058A (ja) | 1998-05-12 | 2002-10-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 97個のヒト分泌タンパク質 |
WO1999067382A2 (en) | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
KR100553300B1 (ko) | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 방법 |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
ES2291198T3 (es) | 1999-07-20 | 2008-03-01 | Genentech, Inc. | Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico. |
US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US20040249141A1 (en) | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
DE60141236D1 (de) | 2000-10-16 | 2010-03-18 | Genentech Inc | Behandlungsverfahren unter Verwendung von WISP-Polypeptiden |
US20030027751A1 (en) | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
JP5105696B2 (ja) | 2001-11-16 | 2012-12-26 | ジェネンテック, インコーポレイテッド | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
EA200500475A1 (ru) | 2002-09-09 | 2005-10-27 | Нектар Терапеутикс Ал, Корпорейшн | Водорастворимые полимерные алканалы |
DE102004013955B4 (de) * | 2004-03-22 | 2007-06-14 | Strathmann Biotech Gmbh & Co. Kg | Verfahren zur Herstellung von rekombinanter RNase A |
AU2004319642A1 (en) * | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
US20110097330A1 (en) | 2005-03-11 | 2011-04-28 | Genentech, Inc. | Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
US7807464B2 (en) | 2005-05-24 | 2010-10-05 | Whitehead Institute For Biomedical Research | Methods for expansion and analysis of cultured hematopoietic stem cells |
EP2094280A1 (en) | 2006-12-06 | 2009-09-02 | Seikagaku Corporation | Pharmaceutical agent having long-lasting effect of treating arthritic disorders |
JP5484063B2 (ja) * | 2006-12-08 | 2014-05-07 | レキシコン ファーマシューティカルズ インコーポレーテッド | Angptl3に対するモノクローナル抗体 |
WO2008137641A2 (en) | 2007-05-04 | 2008-11-13 | Whitehead Institute For Biomedical Research | Ex vivo expansion of human hematopoietic stem cells |
IN2012DN00572A (es) | 2009-07-14 | 2015-06-12 | Scripps Research Inst | |
US9732143B2 (en) * | 2011-02-03 | 2017-08-15 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
CN104619727B (zh) | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
MA38369B1 (fr) * | 2013-03-08 | 2018-10-31 | Novartis Ag | Peptides et compositions pour le traitement d'une lesion de l'articulation |
JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
-
2014
- 2014-03-07 MA MA38369A patent/MA38369B1/fr unknown
- 2014-03-07 US US14/201,694 patent/US9301971B2/en active Active
- 2014-03-10 AR ARP140100777A patent/AR095076A1/es active IP Right Grant
-
2016
- 2016-02-24 US US15/052,029 patent/US9868771B2/en active Active
- 2016-07-18 US US15/212,702 patent/US9745358B2/en active Active
-
2017
- 2017-07-26 US US15/660,914 patent/US10239927B2/en active Active
- 2017-12-07 US US15/835,290 patent/US10533042B2/en active Active
-
2019
- 2019-02-07 US US16/270,371 patent/US11111283B2/en active Active
- 2019-11-25 US US16/694,356 patent/US11370820B2/en active Active
-
2020
- 2020-12-11 AR ARP200103442A patent/AR120721A2/es unknown
-
2022
- 2022-05-24 US US17/664,810 patent/US20220402987A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10239927B2 (en) | 2019-03-26 |
US20190161527A1 (en) | 2019-05-30 |
US11370820B2 (en) | 2022-06-28 |
US11111283B2 (en) | 2021-09-07 |
MA38369B1 (fr) | 2018-10-31 |
US9301971B2 (en) | 2016-04-05 |
US20140256643A1 (en) | 2014-09-11 |
US20170327552A1 (en) | 2017-11-16 |
US20220402987A1 (en) | 2022-12-22 |
US20160376337A1 (en) | 2016-12-29 |
MA38369A1 (fr) | 2017-11-30 |
US10533042B2 (en) | 2020-01-14 |
AR095076A1 (es) | 2015-09-16 |
US20200079830A1 (en) | 2020-03-12 |
US20160244491A1 (en) | 2016-08-25 |
US9745358B2 (en) | 2017-08-29 |
US9868771B2 (en) | 2018-01-16 |
US20180194823A1 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
NZ730752A (en) | Pharmaceutical compositions comprising peptide variants and methods of use thereof | |
UA118167C2 (uk) | Пептид та його застосування | |
EA201792245A1 (ru) | Биоконъюгаты и их применения | |
CL2016001405A1 (es) | A peptide mixture | |
AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
UY35462A (es) | Formulación de un polipéptido del factor viii. | |
EA201792307A1 (ru) | Способы репарации и регенерации тканей | |
MX2017006748A (es) | Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades. | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas | |
EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
MX2017008994A (es) | Formulacion de peptidos inhibidores mk2. | |
BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
CL2017003201A1 (es) | Variantes de il-37 | |
MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. |